Absenteeism among employees with irritable bowel syndrome

Managed Care Interface

Volumn 17, Issue 5, 2004, Pages 28-32

  Zacker, Christopher ^a   Chawla, Anita J ^b   Wang, Shaohung ^c   Albers, Leigh Ann ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GENENTECH INC   (United States)

^c MEDSTAT GROUP   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ADULT; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; DISABILITY; EMPLOYEE; FEMALE; HEALTH CARE COST; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE;

ABSENTEEISM; ADOLESCENT; ADULT; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; UNITED STATES;

EID: 2542589387     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Broadhead WE, Blazer DG, George LK, et al: Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990;264:2524-2528.
2. Comstock GW, Stone RW, Tonascia JA, et al: Respiratory survey findings as predictors of disability from respiratory diseases. Am Rev Respir Dis 1981;124:367-371.
3. Persson U: The indirect costs of morbidity in type II diabetic patients. Pharmacoeconomics 1995;8(suppl 1):28-32.
4. Hu XH, Markson LE, Lipton RB, et al: Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 1999;159:813-818.
5. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force: Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97(suppl 11):S1-S5.
6. Thompson WG, Longstreth GF, Drossman DA, et al: Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl 2):43-47.
7. Ringel Y, Drossman DA: Toward a positive and comprehensive diagnosis of irritable bowel syndrome. Medscape Gastroenterol 2000;2(6):1-10.
8. Lembo TJ, Fink RN: Clinical assessment of irritable bowel syndrome. J Clin Gastroenterol 2002;35(suppl 1):31-36.
9. Thompson WG, Heaton KW, Smyth GT, et al: Irritable bowel syndrome in general practice: Prevalence, characteristics, and referral. Gut 2000;46(1):78-82.
10. Everhart JE, Renault PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991;100:998-1005.
11. Camilleri M, Heading RC, Thompson WG: Consensus report: Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1407-1430.
12. Martin R, Barron JJ, Zacker C: Irritable bowel syndrome: Toward a cost-effective management approach. Am J Manag Care 2001;7(suppl 8): 268-275.
13. Drossman DA, Li Z, Andruzzi E, et al: U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-1580.
14. Leong SA, Barghout V, Birnbaum HG, et al: The economic consequences of irritable bowel syndrome: A US employer perspective. Arch Intern Med 2003;163:929-935.
15. Mullahy J: Much ado about two: Reconsidering retransformation and the two-part model in health econometrics. J Health Econ 1998;17:247-281.
16. Henke CJ, Levin TR, Henning JM, et al: Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000;95:788-792.
17. Gralnek IM: Health care utilization and economic issues in irritable bowel syndrome. Eur J Surg Suppl 1998;164(suppl 583):73-76.
18. Wells NE, Hahn BA, Whorwell PJ: Clinical economics review: Irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:1019-1030.
19. Hahn BA, Yan S, Strassels S: Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999;60(1):77-81.
20. Levy RL, Von Korff M, Whitehead WE, et al: Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122-3129.
21. Camilleri M, Williams DE: Economic burden of irritable bowel syndrome: Proposed strategies to control expenditures. Pharmacoeconomics 2000;17:331-338.
22. Hahn BA, Kirchdoerfer LJ, Fullerton S, et al: Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997;11:553-559.
23. Longstreth GF, Wilson A, Knight K, et al: Irritable bowel syndrome, health care use, and costs: A U.S. managed care perspective. Am J Gastroenterol 2003;98:600-607.
24. Burton WN, Conti DJ, Chen CY, et al: The role of health risk factors and disease in worker productivity. J Occup Environ Med 1999;41:863-877.
25. Rizzo JA, Abbott TA III, Pashko S: Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996;5:249-265.
26. Manning WG, Newhouse JP, Duan N, et al: Health insurance and the demand for medical care: Evidence from a randomized experiment. Am Econ Rev 1987;77:251-277.
27. Jhingran P, Decker C, Ricci JF, et al: Impact of Lotronex on time lost from work in female patients with diarrhea-predominant IBS (abstract). Am J Gastroenterol 2000;95:2631.
28. Crystal-Peters J, Crown WH, Goetzel RZ, et al: The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000;6:373-378.